Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-27T19:59:32.746Z Has data issue: false hasContentIssue false
  • English
  • Français

Keeping up with the clinical advances: tardive dyskinesia

Published online by Cambridge University Press:  04 September 2019

Mazen T. Elkurd  and
Laxman Bahroo
Mazen T. Elkurd
Affiliation:
Department of Neurology, Medstar Georgetown University Hospital, Georgetown, Washington DC, USA
Laxman Bahroo*
Affiliation:
Department of Neurology, Medstar Georgetown University Hospital, Georgetown, Washington DC, USA
*
*Address correspondence to: Laxman Bahroo, Medstar Georgetown University Hospital, 3800 Reservoir Road, N.W., Georgetown 20007, Washington, DC, USA. (Email: [email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

Tardive dyskinesia (TD) was first described in 1964, but treatment for this sometimes poorly characterized condition lagged decades as it was labored by medico-legal implications. TD has often been lumped with other medication-induced disorders and incorrectly classified as extrapyramidal symptoms. TD is likely to be under-recognized for many of these reasons. Though diverse in its presentations, TD is distinct in terms of time course, pathophysiology, and phenomenology.

Keywords

Tardive dyskinesiaclinical advancesTDDRBAParkinsonism
Type
CME Review Article
Information
CNS Spectrums , Volume 24 , Issue S1: CME SUPPLEMENT , August 2019 , pp. 70 - 81
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This activity is supported by an unrestricted educational grant from Neurocrine Continental, Inc., a wholly-owned subsidiary of Neurocrine Biosciences, Inc.

References

REFERENCES:

DSM V Update. https://dsm.psychiatryonline.org/pb-assets/dsm/update/DSM5Update2016.pdf. Accessed March 19, 2019.Google Scholar
Chandra, NC, Sheth, SA, Mehta, RY, et al. Severe tardive dystonia on low dose short duration exposure to atypical antipsychotics: factors explored. Indian J Psychol Med. 2017; 39(1): 96–98. doi: 10.4103/0253-7176.198938 CrossRefGoogle ScholarPubMed
Cloud, LJ, Zutshi, D, Factor, SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurother J Am Soc Exp Neurother. 2014; 11(1): 166–176. doi: 10.1007/s13311-013-0222-5 Google ScholarPubMed
Fernandez, HH, Krupp, B, Friedman, JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001; 56(6): 805–807.CrossRefGoogle ScholarPubMed
Glazer, WM, Morgenstern, H, Schooler, N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990; 157: 585–592.CrossRefGoogle ScholarPubMed
Klawans, HL, Tanner, CM, Barr, A. The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol. 1984; 7(2): 153–159.CrossRefGoogle ScholarPubMed
Modestin, J, Wehrli, MV, Stephan, PL, et al. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res. 2008; 100(1–3): 97–107. doi: 10.1016/j.schres.2007.10.018 CrossRefGoogle ScholarPubMed
Zutshi, D, Cloud, LJ, Factor, SA. Reversibility of Tardive syndromes. Presented at the: 64th Annual Meeting of the American Academy of Neurology; 2012; New Orleans, LA.Google Scholar
Hunter, C, Kenney, C, Mejia, N, et al. Medications associated with onset of Tardive Dyskinesia. Presented at the: Baylor College of Medicine. https://www.bcm.edu/neurology/pdf/poster_pdcmdc_Meds_TDysk_ANA.pdf. Accessed March 17, 2019.Google Scholar
Waln, O, Jankovic, J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Hyperkinetic Mov. 2013; 3: 1–11.Google ScholarPubMed
Fahn, S, Jankovic, J, Hallett, M. Principles and Practice of Movement Disorders. 2nd ed. Philadelphia, PA: Saunders; 2011.Google Scholar
Casey, DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000; 61(Suppl 4): 5–9.Google ScholarPubMed
Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008; 21(2): 151–156. doi: 10.1097/YCO.0b013e3282f53132 CrossRefGoogle ScholarPubMed
Carbon, M, Hsieh, C-H, Kane, JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017; 78(3): e264–e278. doi: 10.4088/JCP.16r10832 CrossRefGoogle ScholarPubMed
Carbon, M, Kane, JM, Leucht, S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry Off J World Psychiatr Assoc WPA. 2018; 17(3): 330–340. doi: 10.1002/wps.20579 Google ScholarPubMed
Cutler, A, Caroff, S, Tanner, C, et al. 117 RE-KINECT: real-world dyskinesia screening study and registry in patients taking antipsychotic agents: interim baseline burden of illness results. CNS Spectr. 2018; 23(1): 74–74. doi: 10.1017/S1092852918000159 CrossRefGoogle Scholar
Dhir, A, Schilling, T, Abler, V, et al. Estimation of epidemiology of Tardive Dyskinesia in the United States (P2. 018). 2017.Google Scholar
Gharabawi, GM, Bossie, CA, Lasser, RA, et al. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res. 2005; 77(2–3): 119–128. doi: 10.1016/j.schres.2005.03.008 CrossRefGoogle ScholarPubMed
Jain, R, Correll, CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018; 79(2): 16–23. doi: 10.4088/JCP.nu17034ah1c CrossRefGoogle ScholarPubMed
Lerner, V, Chanoch Miodownik, VL. Evidence-based guideline: treatment of tardive syndromes Report of the Guideline Development Subcommittee of the American Academy of Neurology. March 2019. https://n.neurology.org/content/evidence-based-guideline-treatment-tardive-syndromes-report-guideline-development. Accessed March 8, 2019.Google Scholar
Aia, PG, Revuelta, GJ, Cloud, LJ, et al. Tardive dyskinesia. Curr Treat Options Neurol. 2011; 13(3): 231–241. doi: 10.1007/s11940-011-0117-x CrossRefGoogle ScholarPubMed
Mizoguchi, K, Yokoo, H, Yoshida, M, et al. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism. Brain Res. 1994; 662(1): 255–258. doi: 10.1016/0006-8993(94)90821-4 CrossRefGoogle ScholarPubMed
Angus, S, Sugars, J, Boltezar, R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997; 17(2): 88.CrossRefGoogle ScholarPubMed
Pappa, S, Tsouli, S, Apostolou, G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010; 33(6): 271–275.CrossRefGoogle ScholarPubMed
Tamminga, CA, Smith, RC, Ericksen, SE, et al. Cholinergic influences in tardive dyskinesia. Am J Psychiatry. 1977; 134(7): 769–774. doi: 10.1176/ajp.134.7.769 Google ScholarPubMed
Wirshing, WC, Freidenberg, DL, Cummings, JL, et al. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychopharmacol. 1989; 9(6): 407–411.CrossRefGoogle ScholarPubMed
Greil, W, Haag, H, Rossnagl, G, et al. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984; 145: 304–310.CrossRefGoogle ScholarPubMed
Bergman, H, Soares-Weiser, K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018; 1. doi: 10.1002/14651858.CD000204.pub2 Google ScholarPubMed
Chen, JJ, Ondo, WG, Dashtipour, K, et al. . Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012; 34(7): 1487–1504. doi: 10.1016/j.clinthera.2012.06.010 CrossRefGoogle ScholarPubMed
Leung, JG, Breden, EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011; 45(4): 525–531. doi: 10.1345/aph.1P312 CrossRefGoogle ScholarPubMed
Ondo, WG, Hanna, PA, Jankovic, J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999; 156(8): 1279–1281.Google ScholarPubMed
Thaker, GK, Nguyen, JA, Strauss, ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990; 147(4): 445–451. doi: 10.1176/ajp.147.4.445 Google ScholarPubMed
Wright, C, Downing, J, Mungall, D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013; 4. doi: 10.3389/fneur.2013.00192 CrossRefGoogle ScholarPubMed
Chen, P-H, Liu, H-C. Rapid improvement of neuroleptic-induced tardive dyskinesia with levetiracetam in an interictal psychotic patient. J Clin Psychopharmacol. 2010; 30(2): 205–207. doi: 10.1097/JCP.0b013e3181d3caf0 CrossRefGoogle Scholar
Levetiracetam as a treatment for tardive dyskinesia: a case report Neurology. https://n.neurology.org/content/61/3/419.long. Accessed March 8, 2019.CrossRefGoogle Scholar
Woods, SW, Saksa, JR, Baker, CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008; 69(4): 546–554.CrossRefGoogle ScholarPubMed
Meco, G, Fabrizio, E, Epifanio, A, et al. Levetiracetam in Tardive Dyskinesia. Clin Neuropharmacol. 2006; 29(5): 265–268. doi: 10.1097/01.wnf.0000228807.49044.7d CrossRefGoogle ScholarPubMed
Winblad, B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005; 11(2): 169–182.CrossRefGoogle ScholarPubMed
Libov, I, Miodownik, C, Bersudsky, Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007; 68(7): 1031–1037.CrossRefGoogle ScholarPubMed
Perényi, A, Farkas, A. Propranolol in the treatment of tardive dyskinesia. Biol Psychiatry. 1983; 18(3): 391–394.Google ScholarPubMed
Schrodt, GR, Wright, JH, Simpson, R, et al. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry. 1982; 43(8): 328–331.Google ScholarPubMed
Silver, JM, Yudofsky, SC, Kogan, M, et al. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry. 1986; 143(10): 1290–1292. doi: 10.1176/ajp.143.10.1290 Google ScholarPubMed
Factor, SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord. 2012; 27(13): 1703–1703. doi: 10.1002/mds.25231 CrossRefGoogle ScholarPubMed
Barak, Y, Swartz, M, Shamir, E, et al. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry. 1998; 10(3): 101–105.CrossRefGoogle ScholarPubMed
Pyridoxine. https://www.drugbank.ca/drugs/DB00165. Accessed March 11, 2019.Google Scholar
Cabrini, L, Bergami, R, Fiorentini, D, et al. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. IUBMB Life. 1998; 46(4): 689–697. doi: 10.1080/15216549800204222 CrossRefGoogle Scholar
Lerner, V, Miodownik, C, Kaptsan, A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001; 158(9): 1511–1514. doi: 10.1176/appi.ajp.158.9.1511 CrossRefGoogle ScholarPubMed
Lerner, V, Miodownik, C, Kaptsan, A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007; 68(11): 1648–1654.CrossRefGoogle ScholarPubMed
Zheng, W, Xiang, Y-Q, Ng, CH, et al. Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials. Pharmacopsychiatry. 2016; 49(3): 107–111. doi: 10.1055/s-0042-102884 Google ScholarPubMed
O’Brien, CF, Jimenez, R, Hauser, RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015; 30(12): 1681–1687. doi: 10.1002/mds.26330 CrossRefGoogle ScholarPubMed
Hauser, RA, Factor, SA, Marder, SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017; 174(5): 476–484.CrossRefGoogle ScholarPubMed
Factor, SA, Remington, G, Comella, CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-Year KINECT 3 extension study. J Clin Psychiatry. 2017.CrossRefGoogle ScholarPubMed
Solmi, M, Pigato, G, Kane, JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12: 1215–1238. doi: 10.2147/DDDT.S133205 CrossRefGoogle ScholarPubMed
Stamler, D, Bradbury, M, Brown, F. The pharmacokinetics and safety of deuterated-tetrabenazine (P07.210). Neurology. 2013; 80(7 Supplement): P07.210.Google Scholar
Anderson, KE, Stamler, D, Davis, MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017; 4(8): 595–604.CrossRefGoogle ScholarPubMed
Fernandez, HH, Factor, SA, Hauser, RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia The ARM-TD study. Neurology. 2017; 88(21): 2003–2010.CrossRefGoogle ScholarPubMed
Fernandez, HH, Stamler, D, Davis, MD, et al. Confirmed safety of deutetrabenazine for tardive dyskinesia in a 2-Year open-label extension study. CNS Spectr. 2019; 24(1): 201–201. doi: 10.1017/S1092852919000397 CrossRefGoogle Scholar
Bhidayasiri, R, Fahn, S, Weiner, WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013; 81(5): 463–469. doi: 10.1212/WNL.0b013e31829d86b6 CrossRefGoogle ScholarPubMed
Bhidayasiri, R, Jitkritsadakul, O, Friedman, JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018; 389: 67–75. doi: 10.1016/j.jns.2018.02.010 CrossRefGoogle ScholarPubMed
Ingrezza (TM) [package insert]. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf. Accessed March 20, 2019.Google Scholar
Grigoriadis, DE, Smith, E, Hoare, SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017; 361(3): 454–461. doi: 10.1124/jpet.116.239160 CrossRefGoogle ScholarPubMed
Austedo (TM) [package insert]. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209885lbl.pdf. Accessed March 20, 2019.Google Scholar